New Method of Infusion for Primary Immunodeficiency Could Improve Patients; Quality of Life
source: pixabay.com

New Method of Infusion for Primary Immunodeficiency Could Improve Patients; Quality of Life

A New Study A new study, conducted by CLS Behring, has found that a new method of administration for Hizentra as a treatment for primary immunodeficiency (PI), could improve quality…

Continue Reading New Method of Infusion for Primary Immunodeficiency Could Improve Patients; Quality of Life
Study: Treatment for Follicular Lymphoma Patients Must be Individualized
source: pixabay.com

Study: Treatment for Follicular Lymphoma Patients Must be Individualized

A recent study examined three different follicular lymphoma (FL) patients to try to better understand how the disease presents differently for different individuals. Ultimately, this study has reiterated the importance…

Continue Reading Study: Treatment for Follicular Lymphoma Patients Must be Individualized
New Method Easily Distinguishes Between Multiple Sclerosis and Neuromyelitis Optica
Science!

New Method Easily Distinguishes Between Multiple Sclerosis and Neuromyelitis Optica

  Technological advancement throughout the world will ultimately lead to new ideas and strategies within the medical realm. As reported by Azo Sensors, a team of Brazilian researchers is already…

Continue Reading New Method Easily Distinguishes Between Multiple Sclerosis and Neuromyelitis Optica
Study Has Led to Better Understanding on the Difference Between Activated PI3K Delta Syndrome 1 and 2
source: pixabay.com

Study Has Led to Better Understanding on the Difference Between Activated PI3K Delta Syndrome 1 and 2

APDS Activated PI3K delta syndrome (APDS) is a form of primary immunodeficiency (PI). There are fewer than 100 reported cases of the condition. APDS has two types (1 and 2),…

Continue Reading Study Has Led to Better Understanding on the Difference Between Activated PI3K Delta Syndrome 1 and 2
Answering COVID-19 Questions: What Is Ground Glass Opacity?
(2010). "Imaging lung manifestations of HIV/AIDS". Annals of Thoracic Medicine 5 (4): 201. DOI:10.4103/1817-1737.69106. ISSN 1817-1737. Creative Commons Attribution License

Answering COVID-19 Questions: What Is Ground Glass Opacity?

If you're like me, COVID-19 has become a major part of your life: in research, discussion, or just daily impact. That's no surprise, considering the numbers. At the time of…

Continue Reading Answering COVID-19 Questions: What Is Ground Glass Opacity?

Researchers Add a Third Risk Factor To Alzheimer’s Disease That Affects the Blood Brain Barrier

It is acknowledged in the medical community that clumps of misfolded tau proteins and amyloid-β are markers of Alzheimer’s disease. The evidence presented in recent article in Nature, shows that…

Continue Reading Researchers Add a Third Risk Factor To Alzheimer’s Disease That Affects the Blood Brain Barrier
New Task Force Recommends Shared Decision-Making for Parents and Patients with Juvenile Idiopathic Arthritis
source: pixabay.com

New Task Force Recommends Shared Decision-Making for Parents and Patients with Juvenile Idiopathic Arthritis

  According to a recent article in BioMed Central, an international task force formed in 2018 created guidelines for the treatment of juvenile idiopathic arthritis (JIA). Treatment targets were identified…

Continue Reading New Task Force Recommends Shared Decision-Making for Parents and Patients with Juvenile Idiopathic Arthritis
Exercise Can Reduce Risk of Severe COVID-19 Respiratory Complications, Says UVA Researcher
source: pixabay.com

Exercise Can Reduce Risk of Severe COVID-19 Respiratory Complications, Says UVA Researcher

  According to a release from the UVA Health System Newsroom, Dr. Zhen Yan, PhD, discovered that exercise can reduce or totally stop severe respiratory symptoms associated with acute respiratory…

Continue Reading Exercise Can Reduce Risk of Severe COVID-19 Respiratory Complications, Says UVA Researcher
CureDuchenne Announces Partnership with Myosana Therapeutics for Duchenne Muscular Dystrophy Treatment
source: pixabay.com

CureDuchenne Announces Partnership with Myosana Therapeutics for Duchenne Muscular Dystrophy Treatment

According to a story from the CureDuchenne Blog, CureDuchenne founder and CEO Debra Miller announced that the organization has recently entered into a new partnership with the biotechnology company Myosana…

Continue Reading CureDuchenne Announces Partnership with Myosana Therapeutics for Duchenne Muscular Dystrophy Treatment
Boston Man Tackling Duchenne Muscular Dystrophy Cure After Sibling’s Diagnosis
source: pixabay.com

Boston Man Tackling Duchenne Muscular Dystrophy Cure After Sibling’s Diagnosis

by Jodee Redmond from In The Cloud Copy Rich Horgan is the founder of the Boston-based biotech non-profit, Cure Rare Diseases. The 28-year-old decided to take action over concerns about…

Continue Reading Boston Man Tackling Duchenne Muscular Dystrophy Cure After Sibling’s Diagnosis
Luspatercept Demonstrates Further Benefits in Transfusion-Dependent Beta Thalassemia
source: pixabay.com

Luspatercept Demonstrates Further Benefits in Transfusion-Dependent Beta Thalassemia

According to a story from Hematology Advisor, the drug luspatercept (marketed as Reblozyl) recently demonstrated its ability to reduce transfusion burden in patients with beta thalassemia that depend on regular…

Continue Reading Luspatercept Demonstrates Further Benefits in Transfusion-Dependent Beta Thalassemia
Join This Webcast to Hear the Latest Update for a Phase IIb Nonalcoholic Steatohepatitis Trial
source: pixabay.com

Join This Webcast to Hear the Latest Update for a Phase IIb Nonalcoholic Steatohepatitis Trial

According to a story from Biotech-365, the biopharmaceutical company Inventiva has been forced to change its plans to announce the latest updates for its phase IIb clinical trial. This clinical…

Continue Reading Join This Webcast to Hear the Latest Update for a Phase IIb Nonalcoholic Steatohepatitis Trial